Home › Funds › HARDING LOEVNER LP › GMAB
HARDING LOEVNER LP position in GMAB
GENMAB A/S · Health Care
HARDING LOEVNER LP reported holding 3,086,318 shares of GMAB (GENMAB A/S) in its Q2 2026 13F filing — a position valued at US$86.9M, representing 0.82% of its reported portfolio and ranking #32 among its reported holdings. HARDING LOEVNER LP has disclosed GMAB holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How HARDING LOEVNER LP's GMAB position evolved
HARDING LOEVNER LP first disclosed a stake in GMAB in Q3 2023 at 3,204,230 shares (US$113.0M). Across 12 filings, HARDING LOEVNER LP increased the stake 5 time(s), trimmed it 5 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 3,086,318 shares valued at US$86.9M — a reduction of -145,283 shares quarter over quarter.. Notable position changes include a 27% trim in Q4 2024 (shares fell 6% over the following quarter), a 28% increase in Q1 2025 (shares rose 6% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 3.20M | $113.01M | New |
| Q4 2023 | 3.29M | $97.57M | Add |
| Q1 2024 | 3.29M | $98.54M | Hold |
| Q2 2024 | 2.77M | $69.61M | Reduce |
| Q3 2024 | 3.07M | $74.75M | Add |
| Q4 2024 | 2.24M | $46.82M | Reduce |
| Q1 2025 | 2.88M | $56.44M | Add |
| Q2 2025 | 2.92M | $60.42M | Add |
| Q3 2025 | 3.48M | $106.86M | Add |
| Q4 2025 | 3.37M | $103.85M | Reduce |
| Q1 2026 | 3.23M | $86.70M | Reduce |
| Q2 2026 | 3.09M | $86.90M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GMAB and 13F data
GMAB (GENMAB A/S) is a Health Care company. 30 other funds we track also report a position in GMAB — the largest reported positions include Paradigm Biocapital Advisors LP (US$360.8M), Orbis Allan Gray Ltd (US$312.3M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$188.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GMAB
- Paradigm Biocapital Advisors LP 13.13M sh · $360.77M · Q2 2026
- Orbis Allan Gray Ltd 11.37M sh · $312.28M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 6.87M sh · $188.58M · Q2 2026
- Sofinnova Investments, Inc. 4.05M sh · $111.12M · Q2 2026
- Deep Track Capital, LP 3.00M sh · $82.41M · Q2 2026
More on HARDING LOEVNER LP
FAQ
How long has HARDING LOEVNER LP held GMAB?
HARDING LOEVNER LP has disclosed GMAB holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is HARDING LOEVNER LP's current position in GMAB?
As of Q2 2026, HARDING LOEVNER LP holds 3.09M shares of GMAB (GENMAB A/S), valued at $86.90M, representing 0.82% of its reported portfolio and ranking #32.
Has HARDING LOEVNER LP been buying or selling GMAB?
In the latest 13F filing (Q2 2026), HARDING LOEVNER LP reduced its position in GMAB.
Which other funds hold GMAB?
Other major institutional holders of GMAB include Paradigm Biocapital Advisors LP, Orbis Allan Gray Ltd, DEERFIELD MANAGEMENT COMPANY, L.P., among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.